MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

The need to enhance the immunogenicity of purified subunit antigens has prompted the development of several new adjuvants. However, many of these new molecules have demonstrated a reactogenicity profile that is not suitable for their inclusion in vaccines for human use. In this context, the adjuvant emulsion MF59™ has been developed, tested in combination with different antigens in several animal models and subsequently evaluated in humans. Clinical trials with several MF59-adjuvanted vaccines have been performed in different age groups (from newborns to the elderly) and have shown an increased immunogenicity of coadministered antigens, associated with a high level of safety and tolerability. MF59 has been the first adjuvant to be licensed for human use after alum and, as part of an enhanced influenza vaccine for the elderly, is now available in the marketplace of several countries worldwide.

[1]  R. Gasparini,et al.  Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects , 2004, European Journal of Epidemiology.

[2]  Maria Zambon,et al.  Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. , 2003, Vaccine.

[3]  L. Biasio,et al.  Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. , 2003, Vaccine.

[4]  E. Erbelding.  Glycoprotein D-adjuvant vaccine to prevent genital herpes. , 2003, Current infectious disease reports.

[5]  D. Bernstein,et al.  Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. , 2002, The Journal of infectious diseases.

[6]  R. Burke,et al.  Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. , 2002, The Pediatric infectious disease journal.

[7]  Malbea A Lapete,et al.  Prevention and Control of Influenza Recommendations of the Advisory Committee on Immunization Practices ( ACIP ) , 2004 .

[8]  W. Borkowsky,et al.  Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. , 2001, The Journal of infectious diseases.

[9]  M. Zambon,et al.  Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza , 2001, The Lancet.

[10]  A. Floreani,et al.  Comparison of three different influenza vaccines in institutionalised elderly. , 2001, Vaccine.

[11]  A. Podda.  The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. , 2001, Vaccine.

[12]  W. Borkowsky,et al.  Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  W. Borkowsky,et al.  Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators. , 2000, The Journal of infectious diseases.

[14]  J. Mascola,et al.  A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais. , 2000 .

[15]  M. Hora,et al.  The Adjuvant MF59: A 10-Year Perspective Gary Ott, Ramachandran Radhakrishnan, , 2000 .

[16]  R. Edelman.  An Overview of Adjuvant Use , 2000 .

[17]  N. Cox,et al.  Prevention and control of influenza , 1999, The Lancet.

[18]  R. Sekulovich,et al.  Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. , 1999, The Journal of infectious diseases.

[19]  D. McDonald,et al.  Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. , 1999, Vaccine.

[20]  W. Britt,et al.  A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. , 1999, The Journal of infectious diseases.

[21]  M. Faccini,et al.  Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. , 1999, Vaccine.

[22]  A. Adimora,et al.  Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. , 1999, JAMA.

[23]  M. L. Clements-Mann,et al.  A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. , 1999, Vaccine.

[24]  G. Ott,et al.  Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs. , 1999, Vaccine.

[25]  J. Heeney,et al.  Comparison of Immunity Generated by Nucleic Acid-, MF59-, and ISCOM-Formulated Human Immunodeficiency Virus Type 1 Vaccines in Rhesus Macaques: Evidence for Viral Clearance , 1999, Journal of Virology.

[26]  A. Podda,et al.  Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. , 1999, Vaccine.

[27]  D. McDonald,et al.  Dendritic cells internalize vaccine adjuvant after intramuscular injection. , 1998, Cellular immunology.

[28]  K. Steimer,et al.  Induction of Neutralizing Antibodies to T-Cell Line-Adapted and Primary Human Immunodeficiency Virus Type 1 Isolates with a Prime-Boost Vaccine Regimen in Chimpanzees , 1998, Journal of Virology.

[29]  G. Van Nest,et al.  The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. , 1997, Vaccine.

[30]  A. Wald,et al.  Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. , 1997, The Journal of infectious diseases.

[31]  G. Nest,et al.  MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. , 1996, The Journal of infectious diseases.

[32]  Thomas Matthews,et al.  Safety and Immunogenicity of a Candidate HIV-1 Vaccine in Healthy Adults: Recombinant Glycoprotein (rgp) 120: A Randomized, Double-Blind Trial , 1996, Annals of Internal Medicine.

[33]  S. Plotkin,et al.  Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines. , 1996, The Journal of infectious diseases.

[34]  J. Carlson,et al.  MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. , 1996, Vaccine.

[35]  D. Stablein,et al.  Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. , 1996, AIDS research and human retroviruses.

[36]  K. Steimer,et al.  Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV‐1SF2 , 1995, AIDS.

[37]  C. Dekker,et al.  A Recombinant Glycoprotein Vaccine for Herpes Simplex Type 2: Safety and Efficacy , 1995, Annals of Internal Medicine.

[38]  W. Beckett,et al.  Prevention of respiratory infections in adults. Influenza and pneumococcal vaccines. , 1994 .

[39]  J. Kahn,et al.  Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. , 1994, The Journal of infectious diseases.

[40]  G. Nest,et al.  Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. , 1994, Journal of immunology.

[41]  L. Stanberry,et al.  The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. , 1994, The Journal of infectious diseases.

[42]  A. Weiner,et al.  Vaccination of chimpanzees against infection by the hepatitis C virus. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[43]  S. Segev,et al.  Failure of influenza vaccination in the aged , 1988, Journal of medical virology.

[44]  D. Tyrrell.  Options for the Control of Influenza , 1987 .

[45]  A. Kendal,et al.  Safety and Immunogenicity of a 45-μg Supplemental Dose of Inactivated Split-Virus Influenza B Vaccine in the Elderly , 1986 .

[46]  S. Greenland,et al.  Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports. , 1986, Vaccine.

[47]  A. Kendal,et al.  Safety and immunogenicity of a 45-microgram supplemental dose of inactivated split-virus influenza B vaccine in the elderly. , 1986, The Journal of infectious diseases.

[48]  J. Phair,et al.  Failure to respond to influenza vaccine in the aged: correlation with B-cell number and function. , 1978, The Journal of laboratory and clinical medicine.